Have Been Scheduled
DGX - Upcoming Dividend Payouts
Next Ex-Dividend Date
|Amount||Declare Date||Ex-Dividend Date ▲||Record Date||Pay Date||Payout Type|
|No Upcoming Dividend Dates|
DGX - Dividend Yield & Stock Price History
Current Dividend Yield
DGX - Dividend Payout History
Current Annual Payout
Dividend.com DARS Rating™ Breakdown for DGX
DGX - Dividend Growth History
Last 5 Yrs
Last 3 Yrs
|Reveal Dividend Growth History for DGX.||44.2%||76.5%||2 years|
DGX - Historical Annual Dividend Data & Growth
Payouts Increasing For
|Payout Amount||Calendar Year||Annual Growth|
DGX - Historical Dividend Data
Payouts Increasing For
|Payout Amount||Declared Date||Ex-Dividend Date||Record Date||Pay Date ▼||Qualified Dividend?||Payout Type||Frequency|
Quest Diagnostics (DGX) - News
Ex-dividend dates are very important to dividend investors, since you must purchase a stock prior to its ex-dividend date in order to receive its...
These were some of the biggest dividend stock performers on the upside and the downside in today's market action. Highlights Dick's Sporting...
Another busy day on the Street, as stocks saw some much needed relief and saw 12 companies announce increases to their dividend payouts. Aimco...
These were some of the biggest dividend stock performers on the upside and the downside in today's market action. Highlights Southwest Airlines...
These were some of the biggest dividend stock performers on the upside and the downside in today's market action. Highlights Visa (V) - up...
These were some of the biggest dividend stock performers on the upside and the downside in today's market action. Highlights Barrick Gold...
Quest Diagnostics Q3 Profit Climbs, But Adjusted Net from Continuing Operations Misses Estimates (DGX)Oct 17, 2013Before the opening bell on Thursday, diagnostic testing and services provider Quest Diagnostics Inc (DGX) reported a rise in third quarter profits, despite a decline in revenues. However, both adjusted earnings from continuing operations and revenues came up short of analysts' views. The Madison, New Jersey-based company posted a third quarter net income of $405.1 million, or $2.68 per share, up significantly from the $163.1 million, or $1.01 per share, earned in the same quarter a year ago. Quest Diagnostics' income from continuing operations came in at $402.7 million, or $2.66 per share, versus last year's third quarter income from continuing operations of $158.6 million, or 98 cents per share. On an adjusted basis, the company's net income from continuing operations was $154 million, or $1.02 per share, in the third quarter. According to analysts polled by Thomson Reuters, the company was expected to earn an adjusted $1.17 per share in the quarter. Quest Diagnostics' net revenues in the quarter edged lower to $1.79 billion from $1.82 billion in the prior year. On average, analysts were expecting the company to post revenues of $1.82 billion in the third quarter. Looking ahead to full year results, the company expects earnings from continuing operations to come in between $3.85 and $3.95 per share; previously, Quest Diagnostics had estimated earnings to be between $4.35 and $4.50 per share in fiscal 2013. Revenues are now expected to be 3.5% lower than fiscal 2012 revenues. Analysts are expecting the company to see earnings of $4.23 per share on revenues of $7.22 billion in fiscal 2013. Quest Diagnostics shares were down $1.01, or 1.72%, during morning trading on Thursday. The stock is down 1.41% year-to-date.
These were some of the biggest dividend stock performers on the upside and the downside in today's market action. Highlights Best Buy (BBY) -...
Diagnostic testing, information, and services company Quest Diagnostics Inc (DGX) reported a preview of its third quarter earnings and revenues...
Quest Diagnostics to Acquire ConVerge Diagnostic Services (DGX)Oct 8, 2013On Monday, diagnostic testing provider Quest Diagnostics Inc (DGX) announced that it has entered into an agreement to acquire ConVerge Diagnostic Services LLC from Water Street Healthcare Partners. ConVerge is a full-service laboratory that provides patients, physicians and hospitals with clinical, cytology and anatomic pathology testing services. DGX does not expect this purchase to affect its FY2013 EPS, but expects a modest increase in FY2014 EPS. Steve Rusckowski, President and CEO of DGX commented: "ConVerge is our fourth laboratory acquisition this year, and the second in Massachusetts, underscoring our commitment to the state and New England." "As a regional leader in women's health that is also recognized for customer service, medical expertise and innovation, ConVerge is a strong strategic fit with our business. The addition of ConVerge to the Quest family will extend the range of diagnostic information services patients and providers can access in the region while also combining the considerable medical leadership of both companies to spur new innovations that improve patient outcomes," Rusckowski added. Quest Diagnostics shares were mostly flat during pre-market trading Tuesday. The stock is up 7% YTD.
The Bottom LineShares of Quest Diagnostics Inc (DGX) have a 1.93% yield based on Monday's closing price of $62.25. Quest Diagnostics Inc (DGX) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.4 out of 5 stars. Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.